



# Financial Tear Sheet

## Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

## Stock Information

### PRTK (Common Stock)

|             |                      |
|-------------|----------------------|
| Exchange    | NASDAQ (US Dollar)   |
| Price       | <b>\$22.40</b>       |
| Change (%)  | <b>▼ 0.8 (3.45%)</b> |
| Volume      | 149,196              |
| 52 Week Low | \$9.80               |
| Market Cap  | \$621,850,611        |
| Rolling EPS | -3.82                |
| PE Ratio    | N/A                  |

Shares Outstanding 27,761,188

Data as of 10/23/17 3:38 p.m. ET



## Recent Paratek Pharmaceuticals News & Events

10/06/17 - 8:01 a.m.

Phase 3 Optic Study Microbiology Data Demonstrate Omadacycline has Potent In vitro Activity Against Multiple Pneumonia Pathogens, Including Resistant Bacteria

There are currently no events scheduled.

10/06/17 - 8:01 a.m.

Consistent Efficacy and Safety Profile Observed in New Analyses of OASIS-1 Phase 3 Study of Omadacycline in Patients with Difficult to Treat Comorbid Conditions

10/02/17 - 4:01 p.m.

Paratek Announces Inducement Grants



## SEC Filings

| Filing Date | Form |
|-------------|------|
|-------------|------|

|          |     |
|----------|-----|
| 08/04/17 | 8-K |
|----------|-----|

|          |      |
|----------|------|
| 08/02/17 | 10-Q |
|----------|------|

|          |   |
|----------|---|
| 07/21/17 | 4 |
|----------|---|

|          |   |
|----------|---|
| 07/21/17 | 4 |
|----------|---|

## Management

|               |  |
|---------------|--|
| Randy Brenner | Senior Vice President -<br>Regulatory, Quality and<br>Technical Operations |
|---------------|--|

|                |  |
|----------------|--|
| Jason Burdette | Vice President -<br>Technical Operations |
|----------------|--|

|            |   |
|------------|---|
| Jeanne Jew | Senior Vice President -<br>Business Development |
|------------|---|

|                 |  |
|-----------------|--|
| Raj Padmanabhan | Vice President -<br>Information Technology |
|-----------------|--|

|               |  |
|---------------|--|
| Regina Paglia | Senior Vice President -<br>Human Resources |
|---------------|--|

|                        |   |
|------------------------|---|
| Susan Perkins,<br>J.D. | Vice President -<br>Intellectual Property |
|------------------------|---|

|             |  |
|-------------|--|
| Evan Tzanis | Senior Vice President -<br>Clinical Development &<br>Clinical Operations |
|-------------|--|

|                   |   |
|-------------------|---|
| Michael F. Bigham | Chief Executive Officer<br>and Chairman of the<br>Board |
|-------------------|---|

Evan Loh, M.D.      President, Chief  
Operating Officer and  
Chief Medical Officer

William Haskel      General Counsel and  
Corporate Secretary

Douglas W. Pagán      Chief Financial Officer

Adam Woodrow      Chief Commercial Officer

Data provided by Nasdaq. Minimum 15 minutes delayed.